PTI INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Proteostasis Therapeutics, Inc. Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Proteostasis Therapeutics, Inc. investors ("Proteostasis" or the "Company") PTI concerning the Company and its officers' possible violations of federal securities laws.

On March 20, 2018, Kerrisdale Capital Management LLC published a report alleging that the Company's claimed success of its Phase 2 proof-of-concept trial of PTI-428 "stems almost entirely from the anomalously bad performance of the 4-person placebo group, while, on average, patients taking PTI-428 barely improved." The report also claimed that "Proteostasis has a habit of sweeping unpleasant or confusing findings under the rug." On this news, shares of Proteostasis fell $1.83, or 26%, to close at $5.16 on March 20, 2018, thereby injuring investors.

If you purchased Proteostasis securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180403006678/en/